Long-Residence Time Peptide Antagonist for the Vasopressin V 2 Receptor to Treat Autosomal Dominant Polycystic Kidney Disease
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Xiaochun Xiong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China. Hauptthemen laut MEDLINE: Polycystic Kidney, Autosomal Dominant. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China, Scientific Research Foundation for Talented Scholars in Xuzhou Medical University.
Abstract (Originalsprache)
The dysregulated intracellular cAMP in the kidneys drives cystogenesis and progression in autosomal dominant polycystic kidney disease (ADPKD). Mounting evidence supports that vasopressin V2 receptor (V2R) antagonism effectively reduces cAMP levels, validating this receptor as a therapeutic target. Tolvaptan, an FDA-approved V2R antagonist, shows limitations in its clinical efficacy for ADPKD treatment. Therefore, the pursuit of better-in-class V2R antagonists with an improved efficacy remains pressing. Herein, we synthesized a set of peptide V2R antagonists. Peptide 33 exhibited a high binding affinity for the V2R (Ki = 6.1 ± 1.5 nM) and an extended residence time of 20 ± 1 min, 2-fold that of tolvaptan. This prolonged interaction translated into sustained suppression of cAMP production in washout experiments. Furthermore, peptide 33 exhibited improved efficacies over tolvaptan in both ex vivo and in vivo models of ADPKD, underscoring its potential as a promising lead compound for the treatment of ADPKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China.
ORCID-Profile: Dong Guo
Förderung
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
- Scientific Research Foundation for Talented Scholars in Xuzhou Medical University
- Jiangsu Specially Appointed Professor program
Zitieren
APA
Xiong, X., Wang, N., Zhang, Y., Zhao, W., Pang, N., Fu, K., Zhou, N., Zhou, X., & Guo, D. (2024). Long-Residence Time Peptide Antagonist for the Vasopressin V 2 Receptor to Treat Autosomal Dominant Polycystic Kidney Disease. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00217
Vancouver
Xiong X, Wang N, Zhang Y, Zhao W, Pang N, Fu K, et al. Long-Residence Time Peptide Antagonist for the Vasopressin V 2 Receptor to Treat Autosomal Dominant Polycystic Kidney Disease. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00217
BibTeX
@article{Xiong2024,
author = {Xiong, Xiaochun and Wang, Naiyuan and Zhang, Yixiao and Zhao, Wenchao and Pang, Ningning and Fu, Kequan and Zhou, Nan and Zhou, Xueyan and Guo, Dong},
title = {Long-Residence Time Peptide Antagonist for the Vasopressin V 2 Receptor to Treat Autosomal Dominant Polycystic Kidney Disease},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00217}
}
EUVIMED